Calendar
event
Ex dividend date
25 Sept 2026
calendar_clock
Next Dividend Payment
09 Oct 2026
About National Research Corp
Ticker
info
NRC
Trading on
info
NASDAQ
ISIN
info
US6373722023
Industry
info
Health Information Services
Sector
info
Healthcare
CEO
info
Trent S. Green
Headquarters
info
1245 Q Street, Lincoln, NE, United States, 68508
Employees
info
357
Website
info
nrchealth.com
NRC Health provides analytics and insights to measure and improve patient and employee experience for healthcare organizations in the United States. The company offers market experience solutions, a subscription-based services for improved tracking of awareness, perception, and consistency of healthcare brands; assessment of differentiators; and segmentation tools to evaluate the needs, wants, and behaviors of communities through assessments. It also provides patient experience solutions, a cross-continuum multi-mode digital platform that collects and measures data to improve patient experience, engagement, and loyalty; employee experience solutions, which combines health care with technology comprising engagement, pulse, lifecycle, culture of safety, and magnet RN satisfaction; and consumer experience solution that offers online reputation solutions, community insights, and cross-journey listening through nGage. In addition, the company offers Huey, an AI engine built for Human Understanding that serves as a healthcare experience management companion; and governance solutions provided through national conferences, publications, advisory services, and an online portal for not-for-profit health system boards of directors, executives, and physician leadership. Further, it provides patient experience, service recovery, care transitions, employee engagement, reputation management, rounding, and brand loyalty. The company was formerly known as National Research Corporation and changed its name to NRC Health April 2026. The company was founded in 1981 and is headquartered in Lincoln, Nebraska.
Metrics
BasicAdvanced
Market cap
info
$450M
P/E ratio
info
84.75
EPS
info
$0.24
Dividend Yield
info
3.08%
Beta
info
0.37
Forward P/E ratio
info
17.21
EBIDTA
info
$26.7M
Ex dividend date
info
2026-09-25
Price & volume
Market cap
info
$450M
Average daily volume
info
0.1M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.60
Dividend yield
info
3.08%
Forward dividend per share
info
$0.64
Forward dividend yield
info
3.15%
Payout ratio
info
84.05%
Valuation
P/E ratio
info
84.75
Forward P/E
info
17.21
PEG ratio
info
1.32
Trailing P/E
info
84.75
Price to sales
info
3.21
Price to book
info
68.7
Earnings
EPS
info
$0.24
EPS estimate (current quarter)
info
$0.14
EPS estimate (next quarter)
info
$0.21
EBITDA
info
$26.7M
Revenues (TTM)
info
$140M
Revenues per share (TTM)
info
$6.38
Technicals
Beta
info
0.37
52-week High
info
$23.68
52-week Low
info
$10.74
50-day moving average
info
$20.45
200-day moving average
info
$17.79
Short ratio
info
4.68
Short %
info
21.46%
Management effectiveness
ROE (TTM)
info
42.03%
ROA (TTM)
info
8.13%
Profit margin
info
4.18%
Gross profit margin
info
$86.4M
Operating margin
info
-0.22%
Growth
Quarterly earnings growth (YoY)
info
-44.00%
Quarterly revenue growth (YoY)
info
4.00%
Share stats
Outstanding Shares
info
22.1M
Float
info
11.8M
Insiders %
info
49.79%
Institutions %
info
53.79%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 1 analysts.

Average price target

info
$26.00
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$0.18
-
-
Q3 • 25Beat
$0.08
-
-
Q4 • 25Beat
$0.14
-
-
Q1 • 26Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$34.8M
$3.2M
9.26%
Q1 • 26
$35.4M
$-3.3M
-9.28%
Q2 • 26
1.69%
-201.89%
-200.20%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$135M
$121M
89.97%
Q1 • 26
$136M
$130M
95.19%
Q2 • 26
1.18%
7.05%
5.80%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$7.2M
-
$-6.9M
$5.3M
Q1 • 26
$1.4M
-
$0.7M
$0.1M
Q2 • 26
-80.70%
-
-110.35%
-98.84%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a National Research Corp share?
Collapse

National Research Corp shares are currently traded for undefined per share.

How many shares does National Research Corp have?
Collapse

National Research Corp currently has 22.1M shares.

Does National Research Corp pay dividends?
Collapse

Yes, National Research Corp does pay dividends.

What is National Research Corp 52 week high?
Collapse

National Research Corp 52 week high is $23.68.

What is National Research Corp 52 week low?
Collapse

National Research Corp 52 week low is $10.74.

What is the 200-day moving average of National Research Corp?
Collapse

National Research Corp 200-day moving average is $17.79.

Who is National Research Corp CEO?
Collapse

The CEO of National Research Corp is Trent S. Green.

How many employees National Research Corp has?
Collapse

National Research Corp has 357 employees.

What is the market cap of National Research Corp?
Collapse

The market cap of National Research Corp is $450M.

What is the P/E of National Research Corp?
Collapse

The current P/E of National Research Corp is 84.75.

What is the EPS of National Research Corp?
Collapse

The EPS of National Research Corp is $0.24.

What is the PEG Ratio of National Research Corp?
Collapse

The PEG Ratio of National Research Corp is 1.32.

What do analysts say about National Research Corp?
Collapse

According to the analysts National Research Corp is considered a buy.